Ascendis Company Profile
What is the competitive landscape for ASCENDIS
ASCENDIS has two approved drugs.
There are twenty US patents protecting ASCENDIS drugs.
Summary for Ascendis
| US Patents: | 20 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
| Patent Litigation for Ascendis: | See patent lawsuits for Ascendis |
| PTAB Cases with Ascendis as petitioner: | See PTAB cases with Ascendis as petitioner |
Drugs and US Patents for Ascendis
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ascendis Pharma Bone | YORVIPATH | palopegteriparatide | SOLUTION;SUBCUTANEOUS | 216490-002 | Aug 9, 2024 | RX | Yes | Yes | 12,453,778 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ascendis | YUVIWEL | navepegritide | POWDER;SUBCUTANEOUS | 219164-002 | Feb 27, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Ascendis | YUVIWEL | navepegritide | POWDER;SUBCUTANEOUS | 219164-002 | Feb 27, 2026 | RX | Yes | Yes | 11,154,593 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Ascendis Pharma Bone | YORVIPATH | palopegteriparatide | SOLUTION;SUBCUTANEOUS | 216490-001 | Aug 9, 2024 | RX | Yes | Yes | 11,590,207 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Ascendis Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 101980725 | ⤷ Start Trial |
| South Korea | 20180100625 | ⤷ Start Trial |
| Morocco | 46343 | ⤷ Start Trial |
| Finland | 3518960 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

